USA Far Ocean Group Inc., is implementing a nationwide product recall of its defective supplement sold under the name <"http://www.yourlawyer.com/practice_areas/defective_drugs">â€œU-Prosta Natural support for prostate health,â€ the U.S. food and Drug Administration (FDA) just announced.
USA Far Ocean Group was informed by FDA representatives that its lab analysis of U-Prosta samples found the product contains terazosin, the active ingredient of an FDA-approved drug used to treat Benign Prostatic Hyperplasia (enlarged prostate). This finding makes U-Prosta an unapproved drug.
The most likely adverse health consequences that could occur with the use of this product would be hypotension, dizziness, or syncope (full or partial loss of consciousness). Patients who are currently being treated with prescription medications for high blood pressure or enlarged prostate would be at increased risk of these events. In these patients, the hypotensive events may be more severe. To date, no illnesses have been reported to the company in connection with this product.
The recalled U-Prosta was distributed nationwide via retail stores, Internet sales, and mail order. All of the following recalled U-Prosta products, which are packaged in white plastic bottles and 1-capsule blister packs, are involved:
U-Prosta Dietary Supplement
â€¢ 30 capsules package size; UPC: 689076499255
â€¢ 60 capsules package size; UPC: 88858100030
â€¢ 1 capsule package size: no UPC
Consumers in possession of the affected product are urged to stop using it immediately and return it to the place of purchase for a full refund. USA Far Ocean Group, Inc., which is located at 1609 W. Valley Boulevard, #338, Alhambra, California, 91803, can be reached at its Special Recall number at 1.626.576.1299, Monday through Sunday, between 9:00 a.m. and 5:00 p.m. Pacific Standard Time.
The CPSC advises consumers to contact their physician if they have experienced any problem that may be related to taking this product.
Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA’s MedWatch Program online at www.fda.gov/medwatch/report.htm; by fax at 1.800.FDA.0178; or by regular mail, using the postage-paid FDA form 3500 available at www.fda.gov/MedWatch/getforms.htm, which should be mailed to MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787.